ACell logo — Developing and commercializing advanced extracellular matrix...

ACell

Developing and commercializing advanced extracellular matrix devices for effective tissue and organ repair across various surgical procedures.

Founded 1999 1001-5000 employees Venture round Total: $8.70M Health Care, Manufacturing

General Information

Company Name ACell
Founded Year 1999
Employees 1001-5000
Industries Health Care, Manufacturing
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with ACell. To contact ACell, visit acell.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ACell compare?

A PDF of ACell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ACell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ACell

ACell is a company dedicated to the development and commercialization of advanced extracellular matrix devices used for effective tissue and organ repair during various surgical procedures. Founded in 1999, the company is headquartered in Columbia, Maryland, and operates a manufacturing facility in Lafayette, Indiana. ACell's product line includes MatriStem technology, MatriStem Wound Care Matrix, MatriStem Plastic Surgery Matrix, and MatriStem Hernia Matrix, catering to different medical needs. ACell received its last investment of $8.70M in a Venture Round on 26 April 2011, reflecting investor confidence in the company's innovative medical solutions. With a focus on Health Care and Manufacturing industries, ACell aims to continue providing cutting-edge solutions for tissue and organ repair in both domestic and international surgical settings.

Business keywords: Extracellular Matrix Devices, Tissue Repair, Organ Repair, Surgical Procedures, Regenerative Medicine, MatriStem Technology, Plastic Surgery, Wound Care, Regenerative Medicine Technology, General Surgery, Innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $8.70M -
26 Apr 2011

ACell Alternatives & Competitors

View All Alternatives
ACell vs
Kerecis
Kerecis Iceland

Kerecis is pioneering the use of fish skin and fatty-acids in the cellular therapy and regenerative...

Debt Financing
517 employees
Health Care, Manufacturing
ACell vs
SANUWAVE
SANUWAVE United States

Heal Wounds With Energy First

Post-IPO Equity
54 employees
Biotechnology, Health Care
ACell vs
TendoNova
TendoNova United States

Moving Orthopedics Forward

Venture round
14 employees
Biotechnology, Health Care

FAQ About ACell

Developing and commercializing advanced extracellular matrix devices for effective tissue and organ repair across various surgical procedures.
ACell was founded in 1999.
ACell operates in Health Care and Manufacturing. Its work centres on Extracellular Matrix Devices, Tissue Repair, Organ Repair and Surgical Procedures.
ACell has approximately 1001-5000 employees.
ACell has completed 1 funding round, raising a total of $8.70M. The latest funding stage is Venture round.
Top alternatives and competitors to ACell include Kerecis, SANUWAVE, TendoNova, HydroCision Inc., ViOptix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ACell and Kerecis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ACell, https://bouncewatch.com/company/acell, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes